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Results: The internal movements of the tumour during the 
treatment were in average around 1 mm L-R; 1,2 mm C-C; 1 
mm A-P. 
 
 
Conclusions: ALART is a possible method of treatment for 
very selected patients which need a high qualified multi-
disciplinary team. It is necessary more studies and a possible 
randomized clinical trial with pO2 increase and/or light 
hyperthermia. 
   
EP-1174   
Local dose-effects of lung perfusion utilizing SPECT/CT 
after VMAT lung cancer radiotherapy 
J.M. Mäkitalo1, T. Virén1, J. Heikkilä1, L. Voutilainen1, M. 
Hakulinen2, T. Laitinen2, J. Seppälä1 
1Kuopio University Hospital, Cancer Center, Kuopio, Finland  
2Kuopio University Hospital, Clinical Physiology and Nuclear 
Medicine, Kuopio, Finland  
 
Purpose/Objective: Radiation pneumonitis (RP) is clinically 
important toxicity in radical non-small cell lung cancer 
(NSCLC) radiotherapy (RT). Changes in lung perfusion can be 
discovered before the actual radiation injury develops into 
RP. In this study voxel based analysis for the radiation 
damage from the volumetric-arc therapy (VMAT) treatments 
was investigated by using the lung perfusion as a measure for 
radiation injury. 
Materials and Methods: This study included six patients (age 
67 ± 14 y) with histologically confirmed NSCLC. The patients 
were imaged with a SPECT/CT-scanner (Philips Precedence, 
Philips Healthcare) after Tc-99m labeled macroaggregated 
albumin injection of 118 ± 9 MBq. Patients were imaged in 
treatment position with a slice thickness of 2 mm. Scans 
were acquired before RT (pre-RT) and 3 months after RT 
(post-RT). Planning target volumes (348 ± 134 cm3) and lungs 
were delineated on the CT images. In addition, the lungs 
were divided into three different areas based on the lung 
perfusion, the activities being 0-40%, 40-60% and 60-100% 
from the value of maximum perfusion counts. VMAT 
treatment plans were created in Monaco® treatment 
planning system using energy of 6 MV and Monte Carlo 
calculation algorithm. Lung doses were converted to 2Gy 
equivalents using LQ-model and α/β ratio of 3Gy. Patients 
were treated using Elekta Infinity linear accelerator (Elekta 
AB, Sweden) to a prescription doses of 10×3Gy (n=2) or 
30×2Gy (n=4) with daily CBCT matching. The decrease in the 
perfusion (pre-RT – post-RT) as a function of total dose 
delivered was recorded with a voxel size of 3×3×3 mm3. 
Voxels closer than 9mm to the lung borders and negative 
perfusion reduction were excluded, thus the reperfusion of 
the lung tissue was excluded from the analysis. 
Results: Mean lung dose (MLD) of the studied patients was on 
average 9.0 ± 4.6 Gy. Figure 1 shows an average dose-effect 
relation to lung perfusion after 3 months of RT. With high 
doses (> 30Gy) the relative reduction of the perfusion was 
greatest in the well perfused areas. Furthermore, there was 
a tendency that MLD, volume of the dose of 5Gy and 20Gy 
correlated with perfusion reduction (data not shown). 
However, the variation between individual patients was large 
and the number of patients was limited. 
 
 
 
Figure 1. Changes in perfusion (3 months post-RT) for the 
total lung volume and three different perfusion volumes 
(<40%, 40-60%, >60%) as a function of total dose delivered. 
 
Conclusions: The incorporation of SPECT/CT can take into 
account the variation of inhomogeneous lung perfusion of 
NSCLC patients. There was an increased perfusion defect 
noted in well perfused areas. Severe radiation injury in well 
perfused areas could thus increase the risk of RP. Additional 
data is needed to identify the predictors of lung injury 
caused by RT. Enrollment for further studies are ongoing. 
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Purpose/Objective: Hypofractionated radiotherapy (HypoRT) 
can potentially improve local control with a higher biological 
effect and shorter overall treatment time. Response, local 
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control, toxicity rates and survivals were evaluated in 
patients affected by inoperable advanced stage NSCLC who 
received hypofractionated radiotherapy. 
Materials and Methods: Seventy-two patients with advanced 
NSCLC were enrolled: 20 patients had stage IIIA, 36 patients 
had stage IIIB, and 16 had stage IV disease. Stage IV patients 
presented with ≤ 2 metastatic sites and stable disease. There 
were no restrictions on previous chemotherapy regimens. All 
patients underwent curative HypoRT with total dose 
prescribed 60 Gy in 20 fractions of 3Gy/each. Radiation 
treatment was delivered using an IGRT (Image-Guided 
Radiotherapy) technique to verify correct position. Toxicities 
were graded according to the RTOG morbidity score. 
Survivals were estimated using the Kaplan–Meier method. 
Results: The median follow up was 13 months (range: 4-58 
months). All patients completed radiotherapy and received 
the total dose of 60 Gy to the primary tumor and positive 
lymph nodes (BED=79Gy). The overall response rate after 
radiotherapy was 83%. The 2-year overall survival and 
progression free-survival rates were 43% and 35%, 
respectively. Median time to progression was 12 months. The 
median survival was 20 months. The loco-regional control and 
the metastases-free survival at 2 –years were 52% and 43%, 
respectively. The treatment was well tolerated. Eleven 
patients developed grade 3 acute toxicities (5 pts esophagitis 
and 6 pts pneumonitis). Ten patients developed grade 3 late 
toxicities: 6 pts pneumonitis and 4 patients esophagitis. 
Conclusions: Hypofractionated curative radiotherapy is a 
feasible and well-tolerated treatment for patients with 
locally advanced non-small cell lung cancer. Randomized 
studies are needed to compare HypoRT to the conventional 
treatment.  
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Purpose/Objective: This retrospective study explores the 
impact of SBRT as an aggressive local treatment on the 
disease evolution and survival of patients with 
oligometastatic and locally advanced-unresectable NSCLC. 
Materials and Methods: 209 lesions (190 pulmonary and 19 
adrenal) were irradiated using SBRT between February'08-
March‘14. Among 121 patients treated (KPS ≥70) 86 (71%) 
were oligometastatic which according to our criteria implied 
the presence of ≤ 5 lung-only metastases or ≤ 3 if presented 
in extra-pulmonary sites also. 31 patients (26%) were with 
single metastasis while 55 (45%) with multiple. The primary 
unresectable NSCLC was also treated in 73 patients (60%). 
Histology was squamous carcinoma in 30% of patients, 
adenocarcinoma(ADC) in 48% and other histologies in 22%. 
The median diameter of the lung lesions was 2.5 cm (range 
0.3-8.8) and of the adrenal metastases 3.3 cm (range 1.5-
5.5). SBRT was delivered with VMAT by 6MV LINAC and 
planned by TPS with Montecarlo algorithm. Lung lesions were 
treated in breath hold with 3 dose levels depending on tumor 
site and size: 26 Gy in a single fraction (47%) prescribed to 
the 70% isodose, 36 Gy (28%) and 30 Gy (25%) in 3 fractions to 
the 80% isodose (BED10 to isocenter = 175, 112.5 and 84.4, 
respectively). The adrenal lesions were treated with 36 Gy in 
3 fractions prescribed to the 70% isodose (BED10 to isocenter 
= 143). Set-up and isocenter were assessed by CBCT. The 
response was evaluated after 60 days by CT and PET, and 
every 3 months subsequently. Toxicity was assessed by CTCAE 
score.  
Results:  
 
 
At 1 and 2 years local control rates were 94% and 83%, overall 
survival(OS) rates 77% and 53% and progression free survival 
41% and 23%, respectively (median F.U. 13.5 months, range 
2-78). All of 17 'in field' recurrences observed (16 in lungs and 
1 adrenal), 79% of which were confirmed at the second follow 
up, resulted being in response at the first follow up. The 
probability of local recurrence correlates with histological 
type, lesion diameter and BED10 value. 87% of 'in field' 
recurrences were squamous histological types while ADCs in 
13%. Only 6.7% of 120 lung lesions treated with BED10 > 100 
have relapsed while 19% of 42 treated with BED10 ≤ 100. In a 
subgroup of lesions with a diameter < 2 cm (66 lesions) only 1 
relapsed (1.5%). The probability of progression disease show 
a trend related to the time elapsed between the appearance 
of metastases and SBRT, > 2 lung metastases vs. ≤ 2, multi-
organic metastases vs. only in lung, and squamous histology 
vs. others. We didn’t observe toxicity > G2. 
Conclusions: SBRT for lung and adrenal lesions is a safe and 
effective ablative treatment using high BED10 values (> 100). 
Lower probability of local control is related to squamous 
histological type, lesion diameter > 2cm and BED10 ≤ 100. A 
better OS is correlated with non-squamous histology, shorter 
